BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback